Comparison of Mineral Trioxide Aggregate (MTA) and 20% Formocresol (FC) in Pulpotomized Human Primary Molars - Full Text View

Sponsor:	National Taiwan University Hospital
Collaborator:	University of Michigan
Information provided by:	National Taiwan University Hospital
ClinicalTrials.gov Identifier:	NCT00972556

Purpose

This prospective clinical randomized controlled trial is established to compare the clinical, radiographic, and histological treatment outcomes between MTA and FC in pulpotomized human primary molars at 6, 12, 18, 24 month post-treatment and to test the hypothesis that Gray Mineral Trioxide Aggregate (GMTA) is a viable alternative to Diluted (20%) Formocresol (DFC) in pulpotomies treatment of human primary molars.

Condition	Intervention
Dental Caries Pulpitis	Drug: Gray Mineral Trioxide Aggregate (GMTA) Drug: Diluted (20%) Formocresol (DFC)

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Comparison of Mineral Trioxide Aggregate and 20% Formocresol in Pulpotomized Human Primary Molars :A Long-Term Follow-Up Study

Resource links provided by NLM:

MedlinePlus related topics: Minerals

Drug Information available for: Cresol

U.S. FDA Resources

Further study details as provided by National Taiwan University Hospital:

Primary Outcome Measures:

clinically and radiographically outcomes [ Time Frame: 6, 12, 18, and 24 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

histological outcome [ Time Frame: when the subjective tooth physically exfoliates from oral cavity ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	200
Study Start Date:	September 2009
Estimated Study Completion Date:	July 2014
Estimated Primary Completion Date:	February 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
GMTA: Experimental	Drug: Gray Mineral Trioxide Aggregate (GMTA) Once hemorrhage from the pulp chamber is under control using direct pressure of a sterile cotton pellet, pulp stumps are covered with a MTA paste, obtained by mixing 0.2g GMTA powder with sterile water in a powder to liquid ratio of 3:1 in weight. The GMTA will be then immediately covered with a zinc-oxide eugenol base (IRM) material.
20% FC: Active Comparator	Drug: Diluted (20%) Formocresol (DFC) After the pulp hemostasis is achieved with direct pressure of a sterile cotton pellet, a sterile cotton pellet dampened with 20% DFC will be placed in contact with the pulp for 5 minutes, followed by the immediate placement of a zinc-oxide eugenol base (IRM) material.

Detailed Description:

Background: Formocresol (FC) is the most widely used pulpotomy medicament in the primary dentition. There are concerns associated with this medicament, primarily the carcinogenicity of the chemical and internal resorption of the treated tooth. Recently, Mineral Trioxide Aggregate (MTA) has been suggested with preliminary studies showing promising results.
Study design: This is a prospective clinical randomized controlled trial (RCT), which will be performed at Department of Dentistry, National Taiwan University Hospital, to compare the treatment outcomes between MTA and FC in pulpotomized human primary molars and to evaluate whether GMTA is a viable alternative to DFC in pulpotomies treatment of human primary molars.
Hypotheses:
- Null Hypotheses: there is no clinical, radiographic, or histological difference between GMTA and DFC at 6, 12, 18, 24 month post-treatment when used as a pulp dressing agent in pulpotomized primary molars.
- Alternative Hypotheses: There is a statistically significant difference between GMTA and DFC as a pulpotomy agent. GMTA shows clinical and/or radiographic and/or histological success as a dressing material following pulpotomy in primary human molars and may be a suitable replacement for DFC in primary molar pulpotomy.
Specific Aims:
- The primary aims of this investigation are:
  1. Compare the clinical and radiographic results of GMTA with DFC pulpotomies on vital human primary molars at 6, 12, 18, and 24 months post-operatively.
  2. Assess intraradicular histological changes of the pulpal tissue and root dentin following pulpotomy treatment with GMTA or DFC.
- The secondary aims of this investigation are:
  1. Assess the outcome of GMTA by multiple operators that have been calibrated to the methods of mixing and placing the material.
  2. Assess whether sex, tooth type, arch, and age of patient at time of treatment influence the overall success rate of GMTA pulpotomies.
  3. Compare the radiographic success of the two materials based on both the traditional radiographic assessment criteria adopted by the American Academy of Pediatric Dentistry (AAPD) and the alternative radiographic success criteria adopted by Zurn et al. 2000.
  4. To serve as a basis for future research in the comparison of GMTA and DFC pulpotomies. This will include larger sample size, longer follow-up periods, and a collaborative study with UM group (Prof. Jan C. Hu).

Eligibility

Ages Eligible for Study:	30 Months to 10 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Primary first or second molars with normal pulp, reversible, or irreversible pulpitis, that have vital carious pulp exposures due to caries and whose pulp bled upon entering the pulp chamber.
Teeth in which hemostasis could be achieved with pressure of a saline dampened sterile cotton pellet prior to medicament/material placement.
No clinical symptoms or evidence of pulp degeneration, such as excessive bleeding from the root canal, history of swelling, mobility, or sinus tracts.
Patients with percussion sensitivity or spontaneous and persistent pain but where hemostasis could be achieved with pressure of sterile cotton pellet.
No radiographic signs of internal or external root resorption, inter-radicular and/or periapical bone destruction, or furcation radiolucency.
No more than one-third physiologic root resorption has occurred.
Teeth had not previously been pulpally treated.
Teeth deemed to be restorable with posterior stainless steel crowns.

Exclusion Criteria:

Not present

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00972556

Contacts

Contact: Yuan-Ling Lee, PhD	886-2-23123456 ext 67337	yuanlinglee@ntu.edu.tw
Contact: Hsiao-Hua Chang, MS	886-2-23123456 ext 70251	hhchangpedo@gmail.com

Locations

Taiwan
Department of Dentistry, National Taiwan University Hospital
Taipei, Taiwan, 10048

Sponsors and Collaborators

National Taiwan University Hospital

University of Michigan

Investigators

Principal Investigator:	Yuan-Ling Lee, PhD	Department of Dentistry, National Taiwan University Hospital
Study Chair:	Hsiao-Hua Chang, MS	Department of Dentistry, National Taiwan University Hospital

More Information

No publications provided

Responsible Party:	Department of Dentistry, National Taiwan University Hospital ( Yuan-Ling Lee )
Study ID Numbers:	200905028R
Study First Received:	September 3, 2009
Last Updated:	September 7, 2009
ClinicalTrials.gov Identifier:	NCT00972556 History of Changes
Health Authority:	Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:

Mineral Trioxide Aggregate
Formocresol
pulpotomy
primary molar
treatment outcome

Additional relevant MeSH terms:

Tooth Diseases
Dental Pulp Diseases
Stomatognathic Diseases

Pulpitis
Tooth Demineralization
Dental Caries

ClinicalTrials.gov processed this record on February 08, 2010